<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2224-5421</journal-id>
<journal-title><![CDATA[Revista Cubana de Química]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Cub Quim]]></abbrev-journal-title>
<issn>2224-5421</issn>
<publisher>
<publisher-name><![CDATA[Ediciones UO, Universidad de Oriente]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2224-54212020000100020</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Inmunoterapia aplicada para el tratamiento de cáncer mediante vacunas desarrolladas con biomateriales]]></article-title>
<article-title xml:lang="en"><![CDATA[Immunotherapy to treat cancer by vaccines developed with biomaterials]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rincon-Silva]]></surname>
<given-names><![CDATA[Nelson Giovanny]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Jimenez-Vergara]]></surname>
<given-names><![CDATA[Eylin Yaidith]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rincon-Silva]]></surname>
<given-names><![CDATA[Juan David]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universitat de les Illes Balears  ]]></institution>
<addr-line><![CDATA[Mallorca ]]></addr-line>
<country>España</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad de los Andes  ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad Pedagógica Nacional Secretaria de Educación ]]></institution>
<addr-line><![CDATA[Boyaca ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>04</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>04</month>
<year>2020</year>
</pub-date>
<volume>32</volume>
<numero>1</numero>
<fpage>20</fpage>
<lpage>44</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S2224-54212020000100020&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S2224-54212020000100020&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S2224-54212020000100020&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN El cáncer es una grave enfermedad que implica crecimiento tisular producido por la proliferación continua de células anormales, con capacidad de invasión y destrucción de otros tejidos, amenazando la vida de los pacientes. Con el desarrollo de la medicina, así como de la biotecnología e ingeniería genética, se han logrado importantes avances en la detección y control de esta enfermedad. Sin embargo, este padecimiento continúa asociado a la muerte y al sufrimiento, con elevados costos económicos. Por lo tanto, en esta revisión, se describe la aplicación de algunos biomateriales para la administración de vacunas como vía de tratamiento en algunos tipos de cáncer, como el de mama, colorrectal, pulmón y próstata, de acuerdo con reportes de la organización mundial de la salud y el instituto nacional de salud de Estados Unidos, y artículos en revistas indexadas. Entre los biomateriales incluidos se encuentran las nano y micropartículas, materiales autoensamblados y scaffolds.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT Cancer is a serious disease that involves tissue growth caused by the continuous proliferation of abnormal cells, with the ability to invade and destroy other tissues, threatening the lives of patients. With the development of medicine, as well as biotechnology and genetic engineering, important advances have been made in the detection and control of this disease. However, this condition continues to be associated with death, suffering and high economic costs. Therefore, this review describes the application of some biomaterials for the administration of vaccines as a treatment route in some types of cancer, such as breast, colorectal, lung and prostate, according to reports from the world organization of the health and the national institute of health of the United States, and articles in indexed journals. Among the biomaterials included are nano and microparticles, self-assembled materials and scaffolds.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[biomateriales]]></kwd>
<kwd lng="es"><![CDATA[vacunas]]></kwd>
<kwd lng="es"><![CDATA[cáncer]]></kwd>
<kwd lng="es"><![CDATA[inmunología]]></kwd>
<kwd lng="en"><![CDATA[biomaterials]]></kwd>
<kwd lng="en"><![CDATA[vaccine]]></kwd>
<kwd lng="en"><![CDATA[cancer]]></kwd>
<kwd lng="en"><![CDATA[inmulogy]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[SUDHAKARAN]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[OOMMEN]]></surname>
<given-names><![CDATA[O.]]></given-names>
</name>
<name>
<surname><![CDATA[RADHAKRISHNA]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Perspectives in Cancer Prevention - Translational Cancer Research]]></source>
<year>2014</year>
<edition>1</edition>
<publisher-loc><![CDATA[India ]]></publisher-loc>
<publisher-name><![CDATA[Springer India]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[CALVO]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cancer Core Europe: A European cancer research alliance realizing a research infrastructure with critical mass and programmatic approach to cure cancer in the 21st century]]></article-title>
<source><![CDATA[European Journal of Cancer]]></source>
<year>2018</year>
<volume>103</volume>
<page-range>155-9</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[ZANETTI]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[SACCHETTO]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[COEBERGH]]></surname>
<given-names><![CDATA[J. W.]]></given-names>
</name>
<name>
<surname><![CDATA[ROSSO]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[To accelerate cancer prevention in Europe: Challenges for cancer registries]]></article-title>
<source><![CDATA[European Journal of Cancer]]></source>
<year>2018</year>
<volume>104</volume>
<page-range>151-9</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="">
<collab>INSTITUTO NATIONAL DEL CÁNCER</collab>
<source><![CDATA[Estadísticas del cancer]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="">
<collab>INSTITUTO NACIONAL DEL CÁNCER</collab>
<source><![CDATA[Terapias biológicas para el cáncer]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[KARLSSON]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[VAUGHAN]]></surname>
<given-names><![CDATA[H. J.]]></given-names>
</name>
<name>
<surname><![CDATA[GREEN]]></surname>
<given-names><![CDATA[J. J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Biodegradable Polymeric Nanoparticles for Therapeutic Cancer Treatments]]></article-title>
<source><![CDATA[Annual Review of Chemical and Biomolecular Engineering]]></source>
<year>2018</year>
<volume>9</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>105-27</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[TSORAS]]></surname>
<given-names><![CDATA[A. N.]]></given-names>
</name>
<name>
<surname><![CDATA[CHAMPION]]></surname>
<given-names><![CDATA[J. A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cross-Linked Peptide Nanoclusters for Delivery of Oncofetal Antigen as a Cancer Vaccine]]></article-title>
<source><![CDATA[Bioconjugate Chemistry]]></source>
<year>2018</year>
<volume>29</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>776-85</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[WAFA]]></surname>
<given-names><![CDATA[E. I.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The effect of polyanhydride chemistry in particle-based cancer vaccines on the magnitude of the anti-tumor immune response]]></article-title>
<source><![CDATA[Acta Biomaterialia]]></source>
<year>2017</year>
<volume>50</volume>
<page-range>417-27</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[ZHANG]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[BILLINGSLEY]]></surname>
<given-names><![CDATA[M. M.]]></given-names>
</name>
<name>
<surname><![CDATA[MITCHELL]]></surname>
<given-names><![CDATA[M. J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Biomaterials for vaccine-based cancer immunotherapy]]></article-title>
<source><![CDATA[Journal of Controlled Release]]></source>
<year>2018</year>
<volume>292</volume>
<page-range>256-76</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[MITRAGOTRI]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Devices for overcoming biological barriers: The use of physical forces to disrupt the barriers]]></article-title>
<source><![CDATA[Advanced Drug Delivery Reviews]]></source>
<year>2013</year>
<volume>65</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>100-3</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[HU]]></surname>
<given-names><![CDATA[Z.]]></given-names>
</name>
<name>
<surname><![CDATA[OTT]]></surname>
<given-names><![CDATA[P. A.]]></given-names>
</name>
<name>
<surname><![CDATA[WU]]></surname>
<given-names><![CDATA[C. J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Towards personalized, tumour-specific, therapeutic vaccines for cancer]]></article-title>
<source><![CDATA[Nature Reviews Immunology]]></source>
<year>2017</year>
<volume>18</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>168-82</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[CHEEVER]]></surname>
<given-names><![CDATA[M. A.]]></given-names>
</name>
<name>
<surname><![CDATA[HIGANO]]></surname>
<given-names><![CDATA[C. S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[PROVENGE [Sipuleucel-T] in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine]]></article-title>
<source><![CDATA[Clinical Cancer Research]]></source>
<year>2011</year>
<volume>17</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>3520-6</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[ZHANG]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Peptide Amphiphile Micelle Vaccine Size and Charge Influence the Host Antibody Response]]></article-title>
<source><![CDATA[ACS Biomaterials Science &amp; Engineering]]></source>
<year>2018</year>
<volume>4</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>2463-72</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[AHMED]]></surname>
<given-names><![CDATA[K. K.]]></given-names>
</name>
<name>
<surname><![CDATA[GEARY]]></surname>
<given-names><![CDATA[S. M.]]></given-names>
</name>
<name>
<surname><![CDATA[SALEM]]></surname>
<given-names><![CDATA[A. K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Applying biodegradable particles to enhance cancer vaccine efficacy]]></article-title>
<source><![CDATA[Immunologic Research]]></source>
<year>2014</year>
<volume>59</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>220-8</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[PARK]]></surname>
<given-names><![CDATA[Y. M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nanoparticle-Based Vaccine Delivery for Cancer Immunotherapy]]></article-title>
<source><![CDATA[Immune Network]]></source>
<year>2013</year>
<volume>13</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>177</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[JOSHI]]></surname>
<given-names><![CDATA[V. B.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tumor lysate-loaded biodegradable microparticles as cancer vaccines]]></article-title>
<source><![CDATA[Expert Review of Vaccines]]></source>
<year>2014</year>
<volume>13</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>9-15</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[HAINLINE]]></surname>
<given-names><![CDATA[K. M.]]></given-names>
</name>
<name>
<surname><![CDATA[FRIES]]></surname>
<given-names><![CDATA[C. N.]]></given-names>
</name>
<name>
<surname><![CDATA[COLLIER]]></surname>
<given-names><![CDATA[J. H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Progress toward the clinical translation of bioinspired peptide and protein assemblies]]></article-title>
<source><![CDATA[Advanced Healthcare Materials]]></source>
<year>2018</year>
<volume>7</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1700</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[WONG]]></surname>
<given-names><![CDATA[K. K.]]></given-names>
</name>
<name>
<surname><![CDATA[LI]]></surname>
<given-names><![CDATA[W. A.]]></given-names>
</name>
<name>
<surname><![CDATA[MOONEY]]></surname>
<given-names><![CDATA[D. J.]]></given-names>
</name>
<name>
<surname><![CDATA[DRANOFF]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Advances in Therapeutic Cancer Vaccines]]></article-title>
<source><![CDATA[Advances in Immunology]]></source>
<year>2016</year>
<volume>130</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>191-249</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[RHODES]]></surname>
<given-names><![CDATA[K. R.]]></given-names>
</name>
<name>
<surname><![CDATA[GREEN]]></surname>
<given-names><![CDATA[J. J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[&#8220;Nanoscale artificial antigen presenting cells for cancer immunotherapy]]></article-title>
<source><![CDATA[Molecular Immunology]]></source>
<year>2018</year>
<volume>98</volume>
<page-range>13-8</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[GUO]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Therapeutic cancer vaccines: past, present, and future]]></article-title>
<source><![CDATA[Advances in Cancer Research]]></source>
<year>2013</year>
<volume>119</volume>
<page-range>421-75</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[MCCARTHY]]></surname>
<given-names><![CDATA[E. F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas]]></article-title>
<source><![CDATA[The Iowa Orthopaedic Journal]]></source>
<year>2006</year>
<volume>26</volume>
<page-range>154-8</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[WANG]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[MOONEY]]></surname>
<given-names><![CDATA[D. J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Biomaterial-assisted targeted modulation of immune cells in cancer treatment]]></article-title>
<source><![CDATA[Nature Materials]]></source>
<year>2018</year>
<volume>17</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>761-72</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[MORALES]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[EIDINGER]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[BRUCE]]></surname>
<given-names><![CDATA[A. W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intracavitary Bacillus Calmette-Guerin in the Treatment of Superficial Bladder Tumors]]></article-title>
<source><![CDATA[The Journal of Urology]]></source>
<year>2017</year>
<volume>197</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[SCHEINBERG]]></surname>
<given-names><![CDATA[D. A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Carbon nanotubes as vaccine scaffolds]]></article-title>
<source><![CDATA[Advanced Drug Delivery Reviews]]></source>
<year>2013</year>
<volume>65</volume>
<numero>15</numero>
<issue>15</issue>
<page-range>2016-22</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[MONTOMOLI]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Current adjuvants and new perspectives in vaccine formulation]]></article-title>
<source><![CDATA[Expert Review of Vaccines]]></source>
<year>2011</year>
<volume>10</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1053-61</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[LELEUX]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[ROY]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Micro and Nanoparticle-Based Delivery Systems for Vaccine Immunotherapy: An Immunological and Materials Perspective]]></article-title>
<source><![CDATA[Advanced Healthcare Materials]]></source>
<year>2013</year>
<volume>2</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>72-94</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[RADFORD]]></surname>
<given-names><![CDATA[K. J.]]></given-names>
</name>
<name>
<surname><![CDATA[TULLETT]]></surname>
<given-names><![CDATA[K. M.]]></given-names>
</name>
<name>
<surname><![CDATA[LAHOUD]]></surname>
<given-names><![CDATA[M. H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dendritic cells and cancer immunotherapy]]></article-title>
<source><![CDATA[Current Opinion in Immunology]]></source>
<year>2014</year>
<volume>27</volume>
<page-range>26-32</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[WANG]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inflammation-Triggered Cancer Immunotherapy by Programmed Delivery of CpG and Anti-PD1 Antibody]]></article-title>
<source><![CDATA[Advanced Materials]]></source>
<year>2016</year>
<volume>28</volume>
<numero>40</numero>
<issue>40</issue>
<page-range>8912-20</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[BERGMANN]]></surname>
<given-names><![CDATA[C. P.]]></given-names>
</name>
<name>
<surname><![CDATA[STUMPF]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Topics in Mining, Metallurgy and Materials Engineering Dental Ceramics Microstructure, Properties and Degradation]]></source>
<year>2013</year>
<edition>1</edition>
<publisher-loc><![CDATA[Suiza ]]></publisher-loc>
<publisher-name><![CDATA[Editorial: Springer]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[HOLLINGER]]></surname>
<given-names><![CDATA[J. O]]></given-names>
</name>
</person-group>
<source><![CDATA[An introduction to biomaterials]]></source>
<year>2012</year>
<edition>2</edition>
<publisher-loc><![CDATA[Boca Raton, Florida. USA ]]></publisher-loc>
<publisher-name><![CDATA[CRC Press/Taylor &amp; Francis]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[KUMBAR]]></surname>
<given-names><![CDATA[S. G.]]></given-names>
</name>
<name>
<surname><![CDATA[LAURENCIN]]></surname>
<given-names><![CDATA[C. T.]]></given-names>
</name>
<name>
<surname><![CDATA[DENG]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Natural and Synthetic Biomedical Polymers]]></source>
<year>2014</year>
<edition>1</edition>
<publisher-loc><![CDATA[Ámsterdam, Países Bajos ]]></publisher-loc>
<publisher-name><![CDATA[Elsevier]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[OSORIO-DELGADO]]></surname>
<given-names><![CDATA[M. A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aplicaciones biomédicas de biomateriales poliméricos]]></article-title>
<source><![CDATA[DYNA]]></source>
<year>2017</year>
<volume>84</volume>
<numero>201</numero>
<issue>201</issue>
<page-range>241-5</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[MAK]]></surname>
<given-names><![CDATA[I. W.]]></given-names>
</name>
<name>
<surname><![CDATA[EVANIEW]]></surname>
<given-names><![CDATA[N.,]]></given-names>
</name>
<name>
<surname><![CDATA[GHERT]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Lost in translation: animal models and clinical trials in cancer treatment]]></article-title>
<source><![CDATA[American Journal of Translational Research]]></source>
<year>2014</year>
<volume>6</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>114-8</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[CLAESSON]]></surname>
<given-names><![CDATA[M. H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Why current peptide-based cancer vaccines fail: lessons from the three Es]]></article-title>
<source><![CDATA[Immunotherapy]]></source>
<year>2009</year>
<numero>14</numero>
<issue>14</issue>
<page-range>513-6</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[SALEM]]></surname>
<given-names><![CDATA[M. L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The use of dendritic cells for peptide-based vaccination in cancer immunotherapy]]></article-title>
<source><![CDATA[Methods in Molecular Biology]]></source>
<year>2014</year>
<volume>1139</volume>
<numero>479-503</numero>
<issue>479-503</issue>
</nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[GU]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[MOONEY]]></surname>
<given-names><![CDATA[D. J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Biomaterials and emerging anticancer therapeutics: engineering the microenvironment]]></article-title>
<source><![CDATA[Nature Reviews Cancer]]></source>
<year>2016</year>
<volume>16</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>56-66</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[GOLDBERG]]></surname>
<given-names><![CDATA[M. S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immunoengineering: how nanotechnology can enhance cancer immunotherapy]]></article-title>
<source><![CDATA[Cell]]></source>
<year>2015</year>
<volume>161</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>201-4</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[KOSHY]]></surname>
<given-names><![CDATA[S. T.]]></given-names>
</name>
<name>
<surname><![CDATA[MOONEY]]></surname>
<given-names><![CDATA[D. J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Biomaterials for enhancing anti-cancer immunity]]></article-title>
<source><![CDATA[Current Opinion in Biotechnology]]></source>
<year>2016</year>
<volume>40</volume>
<page-range>1-8</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[BULBAKE]]></surname>
<given-names><![CDATA[U.]]></given-names>
</name>
<name>
<surname><![CDATA[DOPPALAPUDI]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[KOMMINENI]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
<name>
<surname><![CDATA[KHAN]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Liposomal Formulations in Clinical Use: An Updated Review]]></article-title>
<source><![CDATA[Pharmaceutics]]></source>
<year>2017</year>
<volume>9</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[ZUCKER]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[MARCUS]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[BARENHOLZ]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
<name>
<surname><![CDATA[GOLDBLUM]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Liposome drugs&#8217; loading efficiency: a working model based on loading conditions and drug&#8217;s physicochemical properties]]></article-title>
<source><![CDATA[Journal of Controlled Release]]></source>
<year>2009</year>
<volume>139</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>73-80</page-range></nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[BOBO]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date]]></article-title>
<source><![CDATA[Pharmaceutical Research]]></source>
<year>2016</year>
<volume>33</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>2373-87</page-range></nlm-citation>
</ref>
<ref id="B42">
<label>42</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[BALOGH]]></surname>
<given-names><![CDATA[L. P]]></given-names>
</name>
</person-group>
<source><![CDATA[Nanomedicine in cancer]]></source>
<year>2017</year>
<edition>1</edition>
<page-range>21-46</page-range><publisher-loc><![CDATA[USA ]]></publisher-loc>
<publisher-name><![CDATA[Editorial Pan Stanford Publishing]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B43">
<label>43</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[JASS]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[TJÄRNHAGE]]></surname>
<given-names><![CDATA[T.,]]></given-names>
</name>
<name>
<surname><![CDATA[PUU]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[From Liposomes to Supported, Planar Bilayer Structures on Hydrophilic and Hydrophobic Surfaces: An Atomic Force Microscopy Study]]></article-title>
<source><![CDATA[Biophysical Journal]]></source>
<year>2000</year>
<volume>79</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>3153-63</page-range></nlm-citation>
</ref>
<ref id="B44">
<label>44</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[WISCHKE]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[SCHWENDEMAN]]></surname>
<given-names><![CDATA[S. P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Principles of encapsulating hydrophobic drugs in PLA/PLGA microparticles]]></article-title>
<source><![CDATA[International Journal of Pharmaceutics]]></source>
<year>2008</year>
<volume>364</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>298-327</page-range></nlm-citation>
</ref>
<ref id="B45">
<label>45</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[MANOOCHEHRI]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Surface modification of PLGA nanoparticles via human serum albumin conjugation for controlled delivery of docetaxel]]></article-title>
<source><![CDATA[Journal of Pharmaceutical Sciences]]></source>
<year>2013</year>
<volume>21</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>58</page-range></nlm-citation>
</ref>
<ref id="B46">
<label>46</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[QIU]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Polypropylacrylic acid]peptide nanoplexes as a platform for enhancing the immunogenicity of neoantigen cancer vaccines]]></article-title>
<source><![CDATA[Biomaterials]]></source>
<year>2018</year>
<volume>182</volume>
<page-range>82-91</page-range></nlm-citation>
</ref>
<ref id="B47">
<label>47</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[CHIU]]></surname>
<given-names><![CDATA[Y. C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Assembly and Immunological Processing of Polyelectrolyte Multilayers Composed of Antigens and Adjuvants]]></article-title>
<source><![CDATA[Applied Materials &amp; Interfaces]]></source>
<year>2016</year>
<volume>8</volume>
<numero>29</numero>
<issue>29</issue>
<page-range>18722-31</page-range></nlm-citation>
</ref>
<ref id="B48">
<label>48</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[BENCHERIF]]></surname>
<given-names><![CDATA[S. A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Injectable cryogel-based whole-cell cancer vaccines]]></article-title>
<source><![CDATA[Nature Communications]]></source>
<year>2015</year>
<volume>6</volume>
<page-range>7556</page-range></nlm-citation>
</ref>
<ref id="B49">
<label>49</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[WANG]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[In situ formed reactive oxygen species-responsive scaffold with gemcitabine and checkpoint inhibitor for combination therapy]]></article-title>
<source><![CDATA[Science Translational Medicine]]></source>
<year>2018</year>
<volume>10</volume>
<numero>429</numero>
<issue>429</issue>
<page-range>1-13</page-range></nlm-citation>
</ref>
<ref id="B50">
<label>50</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[ALI]]></surname>
<given-names><![CDATA[O. A.]]></given-names>
</name>
<name>
<surname><![CDATA[EMERICH]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[DRANOFF]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[MOONEY]]></surname>
<given-names><![CDATA[D. J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[In situ regulation of DC subsets and T cells mediates tumor regression in mice]]></article-title>
<source><![CDATA[Science Translational Medicine]]></source>
<year>2009</year>
<volume>1</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1-12</page-range></nlm-citation>
</ref>
<ref id="B51">
<label>51</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[LI]]></surname>
<given-names><![CDATA[W. A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The effect of surface modification of mesoporous silica micro-rod scaffold on immune cell activation and infiltration]]></article-title>
<source><![CDATA[Biomaterials]]></source>
<year>2016</year>
<volume>83</volume>
<page-range>249-56</page-range></nlm-citation>
</ref>
<ref id="B52">
<label>52</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[WANG]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tailoring Biomaterials for Cancer Immunotherapy: Emerging Trends and Future Outlook]]></article-title>
<source><![CDATA[Advanced Materials]]></source>
<year>2017</year>
<volume>29</volume>
<numero>29</numero>
<issue>29</issue>
<page-range>1-24</page-range></nlm-citation>
</ref>
<ref id="B53">
<label>53</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[KOSHY]]></surname>
<given-names><![CDATA[S. T.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Injectable nanocomposite cryogels for versatile protein drug delivery]]></article-title>
<source><![CDATA[Acta Biomaterialia]]></source>
<year>2018</year>
<volume>65</volume>
<page-range>36-43</page-range></nlm-citation>
</ref>
<ref id="B54">
<label>54</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[CARD]]></surname>
<given-names><![CDATA[C. M.]]></given-names>
</name>
<name>
<surname><![CDATA[YU]]></surname>
<given-names><![CDATA[S. S.]]></given-names>
</name>
<name>
<surname><![CDATA[SWARTZ]]></surname>
<given-names><![CDATA[M. A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Emerging roles of lymphatic endothelium in regulating adaptive immunity]]></article-title>
<source><![CDATA[The Journal of Clinical Investigation]]></source>
<year>2014</year>
<volume>124</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>943-52</page-range></nlm-citation>
</ref>
<ref id="B55">
<label>55</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[KUAI]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Subcutaneous Nanodisc Vaccination with Neoantigens for Combination Cancer Immunotherapy]]></article-title>
<source><![CDATA[Bioconjugate Chemistry]]></source>
<year>2018</year>
<volume>29</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>771-5</page-range></nlm-citation>
</ref>
<ref id="B56">
<label>56</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[JIANG]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[WANG]]></surname>
<given-names><![CDATA[Q.]]></given-names>
</name>
<name>
<surname><![CDATA[SUN]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Lymph node targeting strategies to improve vaccination efficacy]]></article-title>
<source><![CDATA[Journal of Controlled Release]]></source>
<year>2017</year>
<volume>267</volume>
<page-range>47-56</page-range></nlm-citation>
</ref>
<ref id="B57">
<label>57</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[DUDZIAK]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Differential Antigen Processing by Dendritic Cell Subsets in Vivo]]></article-title>
<source><![CDATA[Science]]></source>
<year>2007</year>
<volume>315</volume>
<numero>5808</numero>
<issue>5808</issue>
<page-range>107-11</page-range></nlm-citation>
</ref>
<ref id="B58">
<label>58</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[QIAN]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Targeting dendritic cells in lymph node with an antigen peptide-based nanovaccine for cancer immunotherapy]]></article-title>
<source><![CDATA[Biomaterials]]></source>
<year>2016</year>
<volume>98</volume>
<page-range>171-83</page-range></nlm-citation>
</ref>
<ref id="B59">
<label>59</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[ZENG]]></surname>
<given-names><![CDATA[Q.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tailoring polymeric hybrid micelles with lymph node targeting ability to improve the potency of cancer vaccines]]></article-title>
<source><![CDATA[Biomaterials]]></source>
<year>2017</year>
<volume>122</volume>
<page-range>105-13</page-range></nlm-citation>
</ref>
<ref id="B60">
<label>60</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[GEISSMANN]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Development of Monocytes, Macrophages, and Dendritic Cells]]></article-title>
<source><![CDATA[Science]]></source>
<year>2010</year>
<volume>327</volume>
<numero>5966</numero>
<issue>5966</issue>
<page-range>656-61</page-range></nlm-citation>
</ref>
<ref id="B61">
<label>61</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[KHAJAH]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Granulocyte-macrophage colonystimulating factor [GM-CSF]: a chemoattractive agent for murine leukocytes in vivo]]></article-title>
<source><![CDATA[Journal of Leukocyte Biology]]></source>
<year>2011</year>
<volume>89</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>945-53</page-range></nlm-citation>
</ref>
<ref id="B62">
<label>62</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[MCKEE]]></surname>
<given-names><![CDATA[A. S.]]></given-names>
</name>
<name>
<surname><![CDATA[MARRACK]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Old and new adjuvants]]></article-title>
<source><![CDATA[Current Opinion in Immunology]]></source>
<year>2017</year>
<volume>47</volume>
<page-range>44-51</page-range></nlm-citation>
</ref>
<ref id="B63">
<label>63</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[LU]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[HOGENESCH]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Kinetics of the inflammatory response following intramuscular injection of aluminum adjuvant]]></article-title>
<source><![CDATA[Vaccine]]></source>
<year>2013</year>
<volume>31</volume>
<numero>37</numero>
<issue>37</issue>
<page-range>3979-86</page-range></nlm-citation>
</ref>
<ref id="B64">
<label>64</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[VIRGINIO]]></surname>
<given-names><![CDATA[V. G.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Assessment of the adjuvant activity of mesoporous silica nanoparticles in recombinant Mycoplasma hyopneumoniae antigen vaccines]]></article-title>
<source><![CDATA[Heliyon]]></source>
<year>2017</year>
<volume>3</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-16</page-range></nlm-citation>
</ref>
<ref id="B65">
<label>65</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[CHEN]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A heterologous prime-boost Ebola virus vaccine regimen induces durable neutralizing antibody response and prevents Ebola virus-like particle entry in mice]]></article-title>
<source><![CDATA[Antiviral Research]]></source>
<year>2017</year>
<volume>145</volume>
<page-range>54-9</page-range></nlm-citation>
</ref>
<ref id="B66">
<label>66</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[CARBONE]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Are PEI-coated SWCNTs conjugated with hepatitis A virus? A chemical study with SEM, Z -potential, EDXD and RT-PCR]]></article-title>
<source><![CDATA[Biomedical Materials]]></source>
<year>2010</year>
<volume>5</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>035001</page-range></nlm-citation>
</ref>
<ref id="B67">
<label>67</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[PANTAROTTO]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Synthesis, Structural Characterization, and Immunological Properties of Carbon Nanotubes Functionalized with Peptides]]></article-title>
<source><![CDATA[Journal of the American Chemical Society]]></source>
<year>2003</year>
<volume>125</volume>
<numero>20</numero>
<issue>20</issue>
<page-range>6160-4</page-range></nlm-citation>
</ref>
<ref id="B68">
<label>68</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[KRUG]]></surname>
<given-names><![CDATA[L. M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer]]></article-title>
<source><![CDATA[Cancer Immunology, Immunotherapy]]></source>
<year>2010</year>
<volume>59</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1467-79</page-range></nlm-citation>
</ref>
<ref id="B69">
<label>69</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[MENG]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Carbon Nanotubes Conjugated to Tumor Lysate Protein Enhance the Efficacy of an Antitumor Immunotherapy]]></article-title>
<source><![CDATA[Small]]></source>
<year>2008</year>
<volume>4</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1364-70</page-range></nlm-citation>
</ref>
<ref id="B70">
<label>70</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[MOCAN]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[IANCU]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effective colon cancer prophylaxis in mice using embryonic stem cells and carbon nanotubes]]></article-title>
<source><![CDATA[International Journal of Nanomedicine]]></source>
<year>2011</year>
<volume>6</volume>
<page-range>1945-54</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
